KUALA LUMPUR (March 9): Kanger International Bhd will receive 10,000 doses of a Covid-19 vaccine developed by state-owned China National Pharmaceutical Group Corp (Sinopharm) for trial purposes.
In a bourse filing today, the group said the 10,000 doses of the vaccine will be for trial purposes and that it will be getting the necessary approvals from the relevant authorities.
“The first batch of vaccines is expected to arrive in May 2021,” Kanger stated.
Sinopharm has Covid-19 vaccine candidates that are undergoing stage 3 clinical trials.
The announcement was made in reference to its plan to rope in K-Star Sports Ltd and Zuellig Pharma Sdn Bhd to distribute the vaccine.
In October 2020, Kanger had signed two agreements with K-Star and Zuellig Pharma. Zuellig Pharma, the largest vaccine distributor in Malaysia and Asia, will facilitate the import, warehousing and distribution of Covid-19 vaccines in Malaysia.
Meanwhile, Kanger’s agreement with K-Star will see the latter appointed as the sales agent of Covid-19 vaccines for private clinics in Malaysia.
In September 2020, Kanger announced that it would be the distributor of Covid-19 vaccines and medical equipment products in Malaysia for China-based Sinopharm Group Hunan Changde Medical Co Ltd.
In a March 1 report by Code Blue, Minister of Science, Technology and Innovation Khairy Jamaluddin said private companies purchasing Covid-19 vaccines must receive regulatory approval from the National Pharmaceutical Regulatory Agency before they can discuss supplying these vaccines to the government-run national immunisation programme.
Shares in Kanger were 5.26% or half a sen higher at 10 sen, valuing it at RM251.46 million, at noon market close. It saw 52.16 million shares done.
Meanwhile, K-Star shares were 10% or a sen higher at 11 sen, valuing it at RM54.34 million. The counter saw 8.45 million shares traded.
MEMORANDUM OF UNDERSTANDING KANGER INTERNATIONAL BERHAD ("KANGER" OR "THE GROUP") UPDATE ON MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN KANGER AND ZUELLIG PHARMA SDN. BHD. ("ZP") KANGER INTERNATIONAL BERHAD
Type Announcement Subject MEMORANDUM OF UNDERSTANDING Description KANGER INTERNATIONAL BERHAD ("KANGER" OR "THE GROUP") UPDATE ON MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN KANGER AND ZUELLIG PHARMA SDN. BHD. ("ZP") Reference is made to the announcement dated 26 October 2020 pertaining to the MOU made between the Kanger and ZP for the purpose of collaboration on the distribution of Covid-19 vaccines in Malaysia.
The Board of Directors of the Company wishes to announce that the Company is being allocated 10,000 doses of vaccines for trial purposes and will be getting approval from relevant authorities.
The first batch of vaccines is expected to arrive in May 2021.
Type Announcement Subject MEMORANDUM OF UNDERSTANDING Description KANGER INTERNATIONAL BERHAD ("KANGER" OR "THE GROUP") UPDATE ON MEMORANDUM OF UNDERSTANDING ("MOU") BETWEEN KANGER AND K-STAR SPORTS LIMITED ("K-STAR") Reference is made to the announcement dated 26 October 2020 pertaining to the MOU made between Kanger and K-Star for the purpose of appointing K-Star (or its subsidiary) as the sale agent of Covid-19 vaccines for the private clinics in Malaysia.
The Board of Directors of the Company wishes to announce that the Company is being allocated 10,000 doses of vaccines for trial purposes and will be getting approval from relevant authorities.
The first batch of vaccines is expected to arrive in May 2021.
@scenery.. You suffer from multiple personalty disorder...maybe you are ular Spam so many thread. You No Angel... Say Vaccine no hope.. Say all scam... NOW manger got private deal.. Now change tone.. Get lost and go theraphy....
March 1 report by Code Blue, Minister of Science, Technology and Innovation Khairy Jamaluddin said private companies purchasing Covid-19 vaccines must receive regulatory approval from the National Pharmaceutical Regulatory Agency before they can discuss supplying these vaccines to the government run national immunisation programme.
Why vaksin still need trial with 10000 doses coming in may? Why other China vaksin no need trial. Just submit documents enuf for NPRA for approval. This News can be 100% sure will bring in for Msia used or not. So far none approved by NPRA right. How can they bring in Vaksin without NPRA approval. Better check properly first dont later goreng again like last time Director to sell share again Or for RI purposes? Correct?
You think Ular interested on kanger kah. bamboo dream still havent show on QR yet now want RI to raise another 200mil again. You better think twice lah. Correct?
All the best to you vaksin dream lah. Msia pre order 66.5mil doses more than enuf to cater for all the population and you think private vaksin still have room to play. Think twice lah. Why gorment not allow private to handle the vaksin. Scare the fake vaksin as reported available in China lah. Go and read more on fake vaksin in China lah. Correct?
Make it simple. Flu virus killed hundred of thousand of Americans yearly. The virus was detected tens of years ago but due to one reason or another, it survives till now. Expecting covid19 virus is as resilient as its peer. All Covid19 vaccines hv diminishing effect. Our PM who was vaccinated in Mar21 has to go for vaccination again in Sep21. Hence, as long as the virus is staying alive with new cases reported daily after completed the first round of vaccination of the eligible citizens, the demand for the vaccine will be here to stay.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
JaBerry
369 posts
Posted by JaBerry > 2021-03-09 11:27 | Report Abuse
I also cut lost. Later q back....lower